186 related articles for article (PubMed ID: 27696306)
1. Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.
Adhikari BB; Goodson JL; Chu SY; Rota PA; Meltzer MI
Drugs R D; 2016 Dec; 16(4):327-338. PubMed ID: 27696306
[TBL] [Abstract][Full Text] [Related]
2. Measles vaccination using a microneedle patch.
Edens C; Collins ML; Ayers J; Rota PA; Prausnitz MR
Vaccine; 2013 Jul; 31(34):3403-9. PubMed ID: 23044406
[TBL] [Abstract][Full Text] [Related]
3. Microneedle patches for vaccination in developing countries.
Arya J; Prausnitz MR
J Control Release; 2016 Oct; 240():135-141. PubMed ID: 26603347
[TBL] [Abstract][Full Text] [Related]
4. A microneedle patch containing measles vaccine is immunogenic in non-human primates.
Edens C; Collins ML; Goodson JL; Rota PA; Prausnitz MR
Vaccine; 2015 Sep; 33(37):4712-8. PubMed ID: 25770786
[TBL] [Abstract][Full Text] [Related]
5. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
Prausnitz MR; Goodson JL; Rota PA; Orenstein WA
Curr Opin Virol; 2020 Apr; 41():68-76. PubMed ID: 32622318
[TBL] [Abstract][Full Text] [Related]
6. Rabies vaccination in dogs using a dissolving microneedle patch.
Arya JM; Dewitt K; Scott-Garrard M; Chiang YW; Prausnitz MR
J Control Release; 2016 Oct; 239():19-26. PubMed ID: 27524283
[TBL] [Abstract][Full Text] [Related]
7. Microneedle Patches as Drug and Vaccine Delivery Platform.
Li J; Zeng M; Shan H; Tong C
Curr Med Chem; 2017; 24(22):2413-2422. PubMed ID: 28552053
[TBL] [Abstract][Full Text] [Related]
8. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa.
Richardson LC; Moss WJ
Pan Afr Med J; 2020; 35(Suppl 1):3. PubMed ID: 32373254
[TBL] [Abstract][Full Text] [Related]
9. The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains.
Wedlock PT; Mitgang EA; Elsheikh F; Leonard J; Bakal J; Welling J; Crawford J; Assy E; Magadzire BP; Bechtel R; DePasse JV; Siegmund SS; Brown ST; Lee BY
Vaccine; 2019 Jan; 37(4):645-651. PubMed ID: 30578088
[TBL] [Abstract][Full Text] [Related]
10. Microneedle patches: usability and acceptability for self-vaccination against influenza.
Norman JJ; Arya JM; McClain MA; Frew PM; Meltzer MI; Prausnitz MR
Vaccine; 2014 Apr; 32(16):1856-62. PubMed ID: 24530146
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Adigweme I; Akpalu E; Yisa M; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Njie A; Bruce A; Royals M; Goodson JL; Prausnitz MR; McAllister D; Rota PA; Henry S; Clarke E
Trials; 2022 Sep; 23(1):775. PubMed ID: 36104719
[TBL] [Abstract][Full Text] [Related]
13. Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.
Joyce JC; Collins ML; Rota PA; Prausnitz MR
Adv Ther (Weinh); 2021 Oct; 4(10):. PubMed ID: 34926791
[TBL] [Abstract][Full Text] [Related]
14. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
16. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice.
Carey JB; Pearson FE; Vrdoljak A; McGrath MG; Crean AM; Walsh PT; Doody T; O'Mahony C; Hill AV; Moore AC
PLoS One; 2011; 6(7):e22442. PubMed ID: 21799855
[TBL] [Abstract][Full Text] [Related]
17. Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.
Fu H; Abbas K; Malvolti S; Gregory C; Ko M; Amorij JP; Jit M
BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37949503
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau.
Byberg S; Fisker AB; Thysen SM; Rodrigues A; Enemark U; Aaby P; Benn CS; Griffiths UK
Glob Health Action; 2017; 10(1):1329968. PubMed ID: 28580855
[TBL] [Abstract][Full Text] [Related]
19. Development of novel double-decker microneedle patches for transcutaneous vaccine delivery.
Ono A; Azukizawa H; Ito S; Nakamura Y; Asada H; Quan YS; Kamiyama F; Katayama I; Hirobe S; Okada N
Int J Pharm; 2017 Oct; 532(1):374-383. PubMed ID: 28855138
[TBL] [Abstract][Full Text] [Related]
20. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
